Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
551-03-012 / 551-03-012 ISMRM Abstract

Relaxation-diffusion MRI biomarkers for Alzheimer’s Disease

Primary: Neuro - Alzheimer's Disease
Secondary: Preclinical Animal & in vitro MR - Biomarkers
551-03-012 · Advanced MRI Biomarkers of Brain Aging, Vascular Health, and Alzheimer’s Disease · Wednesday, 13 May, 4:00 PM–5:36 PM · Power Pitch Theatre 1
551-03-012 · Advanced MRI Biomarkers of Brain Aging, Vascular Health, and Alzheimer’s Disease · Wednesday, 13 May, 4:00 PM–5:36 PM · Power Pitch Theatre 1
Keywords: Alzheimer's Disease Diffusion-relaxation
Accepted
Ning Hua 1, Lee E Goldstein1, RICHARD J RUSHMORE2, Yogesh Rathi3,4, Lipeng Ning4,5
1Radiology, Boston University Medical Campus, Boston, United States of America
2Anatomy and Neurobiology, Boston University Medical Campus, Boston, United States of America
3Brigham and Women’s Hospital, Brigham and Women's Hospital and Harvard Medical School, Boston, United States of America
4Department of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, United States of America
5Brigham and Women's Hospital and Harvard Medical School, Boston, United States of America
Presenting Author: Ning Hua

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. 1. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019;14(1):32. Epub 20190802. doi: 10.1186/s13024-019-0333-5. PubMed PMID: 31375134; PMCID: PMC6679484. [doi] [pmid]
2. 2. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-47. Epub 20160701. doi: 10.1212/WNL.0000000000002923. PubMed PMID: 27371494; PMCID: PMC4970664. [doi] [pmid]
3. 3. Nation DA, Sweeney MD, Montagne A, Sagare AP, D'Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Chui HC, Law M, Toga AW, Zlokovic BV. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270-6. Epub 20190114. doi: 10.1038/s41591-018-0297-y. PubMed PMID: 30643288; PMCID: PMC6367058. [doi] [pmid]
4. 4. Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimers Res Ther. 2019;11(1):34. Epub 20190422. doi: 10.1186/s13195-019-0485-0. PubMed PMID: 31010420; PMCID: PMC6477717. [doi] [pmid]
5. 5. Bjerke M, Engelborghs S. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. J Alzheimers Dis. 2018;62(3):1199-209. doi: 10.3233/JAD-170680. PubMed PMID: 29562530; PMCID: PMC5870045. [doi] [pmid]
6. 6. Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med. 2022;14(1):e14408. Epub 20211203. doi: 10.15252/emmm.202114408. PubMed PMID: 34859598; PMCID: PMC8749476. [doi] [pmid]
7. 7. Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. J Nucl Med. 2022;63(Suppl 1):13S-9S. doi: 10.2967/jnumed.121.263195. PubMed PMID: 35649652; PMCID: PMC9165727. [doi] [pmid]
8. 8. Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24(8):1112-34. Epub 20190111. doi: 10.1038/s41380-018-0342-8. PubMed PMID: 30635637; PMCID: PMC6756230. [doi] [pmid]
9. 9. Mattsson-Carlgren N AE, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, Zetterberg H, Rosen HJ, Rabinovici G, Chai X, Blennow K, Dage JL, Stomrud E, Smith R, Palmqvist S, Hansson O. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Sci Adv. 2020;15;6(16). doi: doi: 10.1126/sciadv.aaz2387; PMCID: PMC7159908. [doi]
10. 10. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497-510. Epub 20080716. doi: 10.1093/cercor/bhn113. PubMed PMID: 18632739; PMCID: PMC2638813. [doi] [pmid]
11. 11. Zhang Y, Londos E, Minthon L, Wattmo C, Liu H, Aspelin P, Wahlund LO. Usefulness of computed tomography linear measurements in diagnosing Alzheimer's disease. Acta Radiol. 2008;49(1):91-7. doi: 10.1080/02841850701753706. PubMed PMID: 18210318. [doi] [pmid]
12. 12. Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, Pachicano M, Joe E, Nelson AR, D’Orazio LM, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Reiman EM, Caselli RJ, Chui HC, Tcw J, Chen Y, Pa J, Conti PS, Law M, Toga AW, Zlokovic BV. APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71-6. doi: 10.1038/s41586-020-2247-3. [doi]
13. 13. Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku JI, Haruyama T, Kitajima K, Furui S. Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. Radiology. 2015;276(1):228-32. doi: 10.1148/radiol.2015142690. [doi]
14. 14. Petitclerc L, Hirschler L, Örzsik B, Asllani I, Van Osch MJP. Arterial spin labeling signal in the CSF: Implications for partial volume correction and blood–CSF barrier characterization. NMR in Biomedicine. 2023;36(3). doi: 10.1002/nbm.4852. [doi]
15. 15. Petitclerc L, Schmid S, Hirschler L, Osch MJP. Combining T2 measurements and crusher gradients into a single ASL sequence for comparison of the measurement of water transport across the blood–brain barrier. Magnetic Resonance in Medicine. 2021;85(5):2649-60. doi: 10.1002/mrm.28613. [doi]
16. 16. Wells JA, Siow B, Lythgoe MF, Thomas DL. Measuring Biexponential Transverse Relaxation of the ASL Signal at 9.4 T to Estimate Arterial Oxygen Saturation and the Time of Exchange of Labeled Blood Water into Cortical Brain Tissue. Journal of Cerebral Blood Flow & Metabolism. 2013;33(2):215-24. doi: 10.1038/jcbfm.2012.156. [doi]
17. 17. Evans PG, Sokolska M, Alves A, Harrison IF, Ohene Y, Nahavandi P, Ismail O, Miranda E, Lythgoe MF, Thomas DL, Wells JA. Non-Invasive MRI of Blood–Cerebrospinal Fluid Barrier Function. Nature Communications. 2020;11(1). doi: 10.1038/s41467-020-16002-4. [doi]
18. 18. Ning L, Gagoski B, Szczepankiewicz F, Westin C-F, Rathi Y. Joint RElaxation-Diffusion Imaging Moments to Probe Neurite Microstructure. IEEE Transactions on Medical Imaging. 2020;39(3):668-77. doi: 10.1109/tmi.2019.2933982. [doi]
19. 19. Ning L. Maximum-entropy and subspace methods for high-resolution relaxation-diffusion distribution estimation. Imaging Neurosci (Camb). 2025;3. Epub 20250819. doi: 10.1162/IMAG.a.113. PubMed PMID: 40843023; PMCID: PMC12365690. [doi] [pmid]
20. 20. Lampinen B, Szczepankiewicz F, Latt J, Knutsson L, Martensson J, Bjorkman-Burtscher IM, van Westen D, Sundgren PC, Stahlberg F, Nilsson M. Probing brain tissue microstructure with MRI: principles, challenges, and the role of multidimensional diffusion-relaxation encoding. Neuroimage. 2023;282:120338. Epub 20230819. doi: 10.1016/j.neuroimage.2023.120338. PubMed PMID: 37598814. [doi] [pmid]
21. 21. Slator PJ, Palombo M, Miller KL, Westin CF, Laun F, Kim D, Haldar JP, Benjamini D, Lemberskiy G, de Almeida Martins JP, Hutter J. Combined diffusion-relaxometry microstructure imaging: Current status and future prospects. Magn Reson Med. 2021;86(6):2987-3011. Epub 20210819. doi: 10.1002/mrm.28963. PubMed PMID: 34411331; PMCID: PMC8568657. [doi] [pmid]
22. 22. Tax CMW. Estimating chemical and microstructural heterogeneity by correlating relaxation and diffusion. In: Topgaard D, editor. Advanced Diffusion Encoding Methods in MRI. Cambridge (UK)2020.
23. 23. Kim D, Doyle EK, Wisnowski JL, Kim JH, Haldar JP. Diffusion-relaxation correlation spectroscopic imaging: A multidimensional approach for probing microstructure. Magn Reson Med. 2017;78(6):2236-49. Epub 20170319. doi: 10.1002/mrm.26629. PubMed PMID: 28317261; PMCID: PMC5605406. [doi] [pmid]
24. 24. Barsoum S, Latimer CS, Nolan AL, Barrett A, Chang K, Troncoso JC, Keene CD, Benjamini D. Multidimensional MRI reveals cortical astrogliosis linked to dementia in Alzheimer's disease. Brain Commun. 2025;7(3):fcaf245. Epub 20250618. doi: 10.1093/braincomms/fcaf245. PubMed PMID: 40585810; PMCID: PMC12203664. [doi] [pmid]
25. 25. Maity S, Gundampati RK, Suresh Kumar TK. NMR Methods to Characterize Protein-Ligand Interactions. Natural Product Communications. 2019;14(5). doi: 10.1177/1934578x19849296. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/551-03-012